403 related articles for article (PubMed ID: 28671018)
1. GPER-1/GPR30 a novel estrogen receptor sited in the cell membrane: therapeutic coupling to breast cancer.
Molina L; Figueroa CD; Bhoola KD; Ehrenfeld P
Expert Opin Ther Targets; 2017 Aug; 21(8):755-766. PubMed ID: 28671018
[TBL] [Abstract][Full Text] [Related]
2. Possible role of phytoestrogens in breast cancer via GPER-1/GPR30 signaling.
Molina L; Bustamante FA; Bhoola KD; Figueroa CD; Ehrenfeld P
Clin Sci (Lond); 2018 Dec; 132(24):2583-2598. PubMed ID: 30545896
[TBL] [Abstract][Full Text] [Related]
3. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.
Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M
Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451
[TBL] [Abstract][Full Text] [Related]
4. ERα-targeted endocrine therapy, resistance and the role of GPER.
Pepermans RA; Prossnitz ER
Steroids; 2019 Dec; 152():108493. PubMed ID: 31518595
[TBL] [Abstract][Full Text] [Related]
5. The G-protein-coupled estrogen receptor, a gene co-expressed with ERα in breast tumors, is regulated by estrogen-ERα signalling in ERα positive breast cancer cells.
Pal U; Manjegowda MC; Singh N; Saikia S; Philip BS; Jyoti Kalita D; Kumar Rai A; Sarma A; Raphael V; Modi D; Chandra Kataki A; Mukund Limaye A
Gene; 2023 Aug; 877():147548. PubMed ID: 37279863
[TBL] [Abstract][Full Text] [Related]
6. GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ERα-positive breast cancer cells.
Liu L; Liu S; Luo H; Chen C; Zhang X; He L; Tu G
Aging (Albany NY); 2021 Jun; 13(12):16178-16197. PubMed ID: 34182538
[TBL] [Abstract][Full Text] [Related]
7. Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER.
Zekas E; Prossnitz ER
BMC Cancer; 2015 Oct; 15():702. PubMed ID: 26470790
[TBL] [Abstract][Full Text] [Related]
8. Continuous Exposure of Breast Cancer Cells to Tamoxifen Upregulates GPER-1 and Increases Cell Proliferation.
Molina L; Bustamante F; Ortloff A; Ramos I; Ehrenfeld P; Figueroa CD
Front Endocrinol (Lausanne); 2020; 11():563165. PubMed ID: 33117280
[TBL] [Abstract][Full Text] [Related]
9. GPER-1 expression is associated with a decreased response rate to primary tamoxifen therapy of breast cancer patients.
Ignatov T; Treeck O; Kalinski T; Ortmann O; Ignatov A
Arch Gynecol Obstet; 2020 Feb; 301(2):565-571. PubMed ID: 31900584
[TBL] [Abstract][Full Text] [Related]
10. Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer.
Tutzauer J; Sjöström M; Bendahl PO; Rydén L; Fernö M; Leeb-Lundberg LMF; Alkner S
PLoS One; 2020; 15(4):e0231786. PubMed ID: 32302351
[TBL] [Abstract][Full Text] [Related]
11. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
12. ER-mediated anti-tumor effects of shikonin on breast cancer.
Yang Y; Gao W; Tao S; Wang Y; Niu J; Zhao P; Rao C; Yang L
Eur J Pharmacol; 2019 Nov; 863():172667. PubMed ID: 31545985
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
Catalano S; Giordano C; Panza S; Chemi F; Bonofiglio D; Lanzino M; Rizza P; Romeo F; Fuqua SA; Maggiolini M; Andò S; Barone I
Breast Cancer Res Treat; 2014 Jul; 146(2):273-85. PubMed ID: 24928526
[TBL] [Abstract][Full Text] [Related]
14. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LM; Fernö M
Breast Cancer Res Treat; 2014 May; 145(1):61-71. PubMed ID: 24715381
[TBL] [Abstract][Full Text] [Related]
15. Proteolytic Targeting Chimeras with Specificity for Plasma Membrane and Intracellular Estrogen Receptors.
Lu AS; Rouhimoghadam M; Arnatt CK; Filardo EJ; Salem AK
Mol Pharm; 2021 Mar; 18(3):1455-1469. PubMed ID: 33600191
[TBL] [Abstract][Full Text] [Related]
16. Two novel GPER agonists induce gene expression changes and growth effects in cancer cells.
Lappano R; Rosano C; Santolla MF; Pupo M; De Francesco EM; De Marco P; Ponassi M; Spallarossa A; Ranise A; Maggiolini M
Curr Cancer Drug Targets; 2012 Jun; 12(5):531-42. PubMed ID: 22414008
[TBL] [Abstract][Full Text] [Related]
17. Expression and Role of the G Protein-Coupled Estrogen Receptor (GPR30/GPER) in the Development and Immune Response in Female Reproductive Cancers.
Hernández-Silva CD; Villegas-Pineda JC; Pereira-Suárez AL
Front Endocrinol (Lausanne); 2020; 11():544. PubMed ID: 32973677
[TBL] [Abstract][Full Text] [Related]
18. G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen.
Ignatov T; Claus M; Nass N; Haybaeck J; Seifert B; Kalinski T; Ortmann O; Ignatov A
Breast Cancer Res Treat; 2019 Feb; 174(1):121-127. PubMed ID: 30478785
[TBL] [Abstract][Full Text] [Related]
19. Identification of Breast Cancer Inhibitors Specific for G Protein-Coupled Estrogen Receptor (GPER)-Expressing Cells.
Aiello F; Carullo G; Giordano F; Spina E; Nigro A; Garofalo A; Tassini S; Costantino G; Vincetti P; Bruno A; Radi M
ChemMedChem; 2017 Aug; 12(16):1279-1285. PubMed ID: 28520140
[TBL] [Abstract][Full Text] [Related]
20. Function of G-Protein-Coupled Estrogen Receptor-1 in Reproductive System Tumors.
Qian H; Xuan J; Liu Y; Shi G
J Immunol Res; 2016; 2016():7128702. PubMed ID: 27314054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
